Clinical outcomes of pembrolizumab combination therapy in heavily pretreated PDTC and anaplastic thyroid cancer
European Thyroid Journal · 2026
DOI: 10.1530/etj-26-0053 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2026. Verfasst von Tim Brandenburg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are rare, aggressive malignancies with limited treatment options. Although targeted therapies for tumours harbouring BRAF V600E mutations or fusions involving NTRK1, NTRK2, NTRK3 or RET have expanded treatment options, most patients lack such actionable alterations and urgently require alternative therapeutic strategies. Immune checkpoint blockade (ICB) has emerged as a promising approach, but its real-world application is limited by restricted trial access, reimbursement challenges and the aggressive course of these diseases.
Methods
We retrospectively analysed the Essen ATC/PDTC cohort (June 2018 to February 2024) to evaluate the real-world efficacy of lenvatinib plus pembrolizumab (LEN-PEM) in heavily pretreated patients, including PDTC cases progressing after two or more prior tyrosine kinase inhibitors and ATC cases treated with upfront (radio-)chemotherapy.
Results
Of the five patients with PDTC, four achieved a partial response and one achieved durable stable disease (>50 months), corresponding to an objective response rate (ORR) of 4/5 and a clinical benefit rate (CBR) of 5/5. Median progression-free survival (PFS) and overall survival (OS) from LEN-PEM initiation were 29.1 and 34.9 months, respectively; median OS from diagnosis was not reached. Among the ten patients with ATC, four achieved a partial response and three achieved stable disease, corresponding to an ORR of 4/10 and a CBR of 7/10. Median PFS and OS from LEN-PEM initiation were 7.6 and 9.9 months, respectively, and median OS from diagnosis was 24.3 months.
Conclusion
LEN-PEM demonstrates meaningful clinical activity in pretreated PDTC and ATC patients, supporting its use as a later-line therapeutic option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen, Germany.
- Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen, Germany.
- Institute of Pathology, University Hospital Essen, University Duisburg-Essen , Essen, Germany.
- Clinic for Nuclear Medicine, University Hospital Essen, University Duisburg-Essen , Essen, Germany.
- Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen , Essen, Germany.
ORCID-Profile: Tim Brandenburg
Zitieren
APA
Brandenburg, T., Machlah, Y. M., Srasra, L. M., Muchalla, P., Theurer, S., Kersting, D., Weber, M. M., Weber, F., Dralle, H., Lahner, H., & Führer, D. (2026). Clinical outcomes of pembrolizumab combination therapy in heavily pretreated PDTC and anaplastic thyroid cancer. European Thyroid Journal. https://doi.org/10.1530/etj-26-0053
Vancouver
Brandenburg T, Machlah YM, Srasra LM, Muchalla P, Theurer S, Kersting D, et al. Clinical outcomes of pembrolizumab combination therapy in heavily pretreated PDTC and anaplastic thyroid cancer. European Thyroid Journal. 2026. doi:10.1530/etj-26-0053
BibTeX
@article{Brandenburg2026,
author = {Brandenburg, Tim and Machlah, Yara Maria and Srasra, Lynn Marlene and Muchalla, Philipp and Theurer, Sarah and Kersting, David and Weber, Manuel Maria and Weber, Frank and Dralle, Henning and Lahner, Harald and Führer, Dagmar},
title = {Clinical outcomes of pembrolizumab combination therapy in heavily pretreated PDTC and anaplastic thyroid cancer},
journal = {European Thyroid Journal},
year = {2026},
doi = {10.1530/etj-26-0053}
}
EUVIMED